Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Papadopoulos

Showing results (601-610 of 722) with videos related to

Pageof 73
Sort By:
Allergy|September 24, 2009
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in EuropeL M Heinzerling, G J Burbach, G Edenharter, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 29, 2013
Clinical relevance is associated with allergen-specific wheal size in skin prick testingT Haahtela, G J Burbach, C Bachert, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Allergy|January 30, 2020
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air<sup>®</sup> AppAnnabelle Bédard, Josep M Antó, Joao A Fonseca, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
Allergy|October 8, 2017
Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergyM R Datema, R van Ree, R Asero, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 28, 2024
Levels of IgE sensitization drive symptom thresholds in allergic rhinitisMaria V Dimou, Paraskevi Xepapadaki, John Lakoumentas, et al.
American Journal of Respiratory and Critical Care Medicine|October 29, 2014
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivoDavid J Jackson, Heidi Makrinioti, Batika M J Rana, et al.
The Lancet. Infectious Diseases|June 20, 2018
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidatesNatalie I Mazur, Deborah Higgins, Marta C Nunes, et al.
Pageof 73

Showing results (601-610 of 722) with videos related to

Sort By:
Pageof 73
Allergy|September 24, 2009
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in EuropeL M Heinzerling, G J Burbach, G Edenharter, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|November 29, 2013
Clinical relevance is associated with allergen-specific wheal size in skin prick testingT Haahtela, G J Burbach, C Bachert, et al.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
Allergy|January 30, 2020
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air<sup>®</sup> AppAnnabelle Bédard, Josep M Antó, Joao A Fonseca, et al.
Allergy|February 18, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Claudio Rocha, Jessica Beltran, et al.
Allergy|October 8, 2017
Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergyM R Datema, R van Ree, R Asero, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 28, 2024
Levels of IgE sensitization drive symptom thresholds in allergic rhinitisMaria V Dimou, Paraskevi Xepapadaki, John Lakoumentas, et al.
American Journal of Respiratory and Critical Care Medicine|October 29, 2014
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivoDavid J Jackson, Heidi Makrinioti, Batika M J Rana, et al.
The Lancet. Infectious Diseases|June 20, 2018
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidatesNatalie I Mazur, Deborah Higgins, Marta C Nunes, et al.
Pageof 73